ArticleAnnals of the rheumatic diseases2007
Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.
Article in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02878161 (Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review.Rheumatology international · 2022Pooled it
- Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions.PharmacoEconomics · 2021Pooled it
- Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial.BMC musculoskeletal disorders · 2009Trial
- Clinical Characteristics and Predictors of Primary Non-Response to Biologic Therapy in Rheumatoid Arthritis and Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2026Article
- Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.Rheumatology (Oxford, England) · 2022Article
- Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab.Protein science : a publication of the Protein Society · 2018Article
- Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.Nature reviews. Rheumatology · 2017Review
- [Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].Zeitschrift fur Rheumatologie · 2015Article
- Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.Expert review of vaccines · 2015Review
- Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.BMC musculoskeletal disorders · 2014Observational
- Genetics of rheumatoid arthritis - a comprehensive review.Clinical reviews in allergy & immunology · 2013Review
- Pharmacogenetics and pharmacogenomics in rheumatology.Immunologic research · 2013Review
- Pharmacogenomics in clinical practice and drug development.Nature biotechnology · 2012Review
- Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab.Modern rheumatology · 2011Article
- Advances in rheumatology: new targeted therapeutics.Arthritis research & therapy · 2011Review
- Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.International ophthalmology · 2011Review
- Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors.Arthritis research & therapy · 2011Article
- Adalimumab (humira™) in ophthalmology: a review of the literature.Middle East African journal of ophthalmology · 2010Article
- Treatment of rheumatoid arthritis: state of the art 2009.Nature reviews. Rheumatology · 2009Review
- Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.Arthritis research & therapy · 2009Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.